¼¼°èÀÇ ¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍ ½ÃÀå
Small-Scale Bioreactors
»óǰÄÚµå : 1788347
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 141 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,183,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,550,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 55¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 24¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 14.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 55¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Àç»ç¿ë °¡´É ¹ÙÀÌ¿À¸®¾×ÅÍ´Â CAGR 12.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 33¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÏȸ¿ë¡¤¹ÙÀÌ¿À¸®¾×ÅÍ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 17.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 6¾ï 3,210¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 14.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍ ½ÃÀåÀº 2024³â¿¡´Â 6¾ï 3,210¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 8¾ï 5,440¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 14.0%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 13.3%¿Í 12.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 11.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅͰ¡ Á¡Á¡ ´õ Áß¿äÇØÁö´Â ÀÌÀ¯´Â ¹«¾ùÀϱî? ¹ÙÀÌ¿ÀÀǾàǰ ¹× »ý¸í°øÇÐ ¿¬±¸¿¡¼­ÀÇ ¿ªÇÒ È®ÀÎ

¹ÙÀÌ¿ÀÀǾàǰ, ¹é½Å, ¼¼Æ÷ ±â¹Ý Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ¿¬±¸, °øÁ¤ ÃÖÀûÈ­, Ãʱ⠴ܰèÀÇ ÀǾàǰ °³¹ß¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´ëÇü »ê¾÷¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ¿Í ´Þ¸®, ¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍ´Â ¹Ì»ý¹°, Æ÷À¯·ù ¼¼Æ÷ ¹× ±âŸ »ý¹°ÇÐÀû ½Ã½ºÅÛÀ» ¼ö ¹Ð¸®¸®ÅÍ¿¡¼­ ¼ö ¸®ÅÍÀÇ ¿ë·®À¸·Î ¹è¾çÇÒ ¼ö ÀÖ´Â Á¦¾îµÈ ȯ°æÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¸®¾×ÅÍ´Â »ý¸í°øÇÐ ¹× Á¦¾à »ê¾÷¿¡¼­ »ó¾÷Àû »ý»êÀ¸·Î È®ÀåÇϱâ Àü¿¡ ¼¼Æ÷ Áõ½Ä Á¶°ÇÀ» ÃÖÀûÈ­ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. Çаè, CRO(ÀÓ»ó½ÃÇè¼öʱâ°ü), ½Å»ý ¹ÙÀÌ¿ÀÅØ ±â¾÷µéµµ ´ë±Ô¸ð »ý»ê¿¡ µû¸¥ ºñ¿ë°ú À§ÇèÀ» ÁÙÀÌ°í ½ÇÇèÀû ¿¬±¸¸¦ ¼öÇàÇϱâ À§ÇØ ¼ÒÇü ¹ÙÀÌ¿À¸®¾×Å͸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á, Àç»ýÀÇ·á, ÇÕ¼º»ý¹°Çп¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì ¼Ö·ç¼ÇÀ» ã´Â ±â¾÷µéÀÇ ¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍ¿¡ ´ëÇÑ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº ¾î¶»°Ô ¼ÒÇü ¹ÙÀÌ¿À¸®¾×Å͸¦ °­È­Çϴ°¡? ÀÚµ¿È­, ¸ð´ÏÅ͸µ, °øÁ¤ Á¦¾îÀÇ ±â¼ú Çõ½Å¿¡ ´ëÇÑ Å½±¸

¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍÀÇ ±â¼ú Çõ½ÅÀº È¿À², ÀçÇö¼º, ÀÚµ¿È­ ´É·ÂÀ» Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ±¤ÇÐ ¼¾¼­ ¹× ºÐ±¤ÇÐ ±â¹Ý ºÐ¼®°ú °°Àº ½Ç½Ã°£ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ ÅëÇÕÀ» ÅëÇØ ¿¬±¸ÀÚµéÀº pH, ¿ëÁ¸ »ê¼Ò, ¿µ¾ç ¼öÁذú °°Àº ÁÖ¿ä ¸Å°³ º¯¼ö¸¦ Á¤È®ÇÏ°Ô ÃßÀûÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀΰøÁö´É(AI) ¹× ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀ» °®Ãá ÀÚµ¿ Á¦¾î ½Ã½ºÅÛÀº ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º Á¶°ÇÀ» ÀûÀÀÀûÀ¸·Î Á¶Á¤ÇÏ¿© ¼¼Æ÷¹è¾ç ¼º´ÉÀ» ÃÖÀûÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ´Â ´ë±Ô¸ð ¼¼Ã´ ¹× ¸ê±ÕÀÇ Çʿ伺À» ¾ø¾Ö°í ±³Â÷ ¿À¿°ÀÇ À§ÇèÀ» ÁÙÀÌ´Â µ¿½Ã¿¡ ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅͰ¡ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. ¼ÒÇüÈ­µÈ °í󸮷® ¹ÙÀÌ¿À¸®¾×ÅÍÀÇ °³¹ßÀº ¿¬±¸¸¦ ´õ¿í °¡¼ÓÈ­Çϰí, ¿©·¯ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ÆÄ¶ó¹ÌÅ͸¦ µ¿½Ã¿¡ ½ÇÇèÇÒ ¼ö ÀÖ´Â º´·Ä ½ÇÇèÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÀçÇö °¡´ÉÇϰí È®Àå °¡´ÉÇÑ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ¹ßÀüÀº ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶ÀÇ ¹Ì·¡¸¦ Çü¼ºÇϰí ÀÖÀ¸¸ç, ¼Ò±Ô¸ð ¹ÙÀÌ¿À ¹ÝÀÀ±â´Â Çö´ë »ý¸í°øÇÐ ¿¬±¸¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â À̽´´Â? ºñ¿ë, È®À强, Ç¥ÁØÈ­ ¹®Á¦¿¡ ´ëÇÑ ´ëÀÀ

¼ÒÇü ¹ÙÀÌ¿À¸®¾×Åʹ äÅÃÀÌ È®´ëµÇ°í ÀÖÀ½¿¡µµ ºÒ±¸ÇÏ°í ºñ¿ë, È®À强, Ç¥ÁØÈ­¿¡ ´ëÇÑ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÚµ¿ Á¦¾î ½Ã½ºÅÛÀ» °®Ãá ÷´Ü ¹ÙÀÌ¿À¸®¾×ÅÍ¿¡ ´ëÇÑ Ãʱâ ÅõÀÚ´Â °íºñ¿ëÀÌ ¼Ò¿äµÉ ¼ö ÀÖÀ¸¸ç, ¼Ò±Ô¸ð ¿¬±¸¼Ò³ª ½Å»ý ¹ÙÀÌ¿À±â¾÷ÀÌ ½±°Ô Á¢±ÙÇÒ ¼ö Àִ ȯ°æÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼Ò±Ô¸ð »ý»ê¿¡¼­ »ó¾÷Àû »ý»êÀ¸·ÎÀÇ ½ºÄÉÀϾ÷Àº ½ºÄÉÀϾ÷ °úÁ¤¿¡¼­ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ÆÄ¶ó¹ÌÅÍÀÇ ÀçÃÖÀûÈ­°¡ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ ¿©ÀüÈ÷ °úÁ¦·Î ³²¾ÆÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸®¾×ÅÍ ¼³°è, ƯÈ÷ ÀÏȸ¿ë ½Ã½ºÅÛ¿¡ ´ëÇÑ º¸ÆíÀûÀΠǥÁØÀÌ ¾ø±â ¶§¹®¿¡ ¼­·Î ´Ù¸¥ °ø±Þ¾÷ü¿Í ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¿öÅ©ÇÃ·Î¿ì °£ÀÇ È£È¯¼º ¹®Á¦°¡ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÚµ¿È­´Â È¿À²¼ºÀ» Çâ»ó½ÃŰÁö¸¸, µ¥ÀÌÅÍ ºÐ¼®°ú ÇÁ·ÎÅäÄÝ ÃÖÀûÈ­¸¦ À§Çؼ­´Â ¼÷·ÃµÈ ÀηÂÀÌ ÇÊ¿äÇϰí, ÈÆ·ÃÀÇ Çʿ伺ÀÌ ³ô¾ÆÁý´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦¸¦ ÇØ°áÇϱâ À§Çؼ­´Â ºñ¿ë È¿À²ÀûÀÎ ¼³°è¸¦ À§ÇÑ Áö¼ÓÀûÀÎ Çõ½Å, ¿øÈ°ÇÑ ½ºÄÉÀϾ÷À» À§ÇÑ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¸ðµ¨¸µ °³¼±, ¹ÙÀÌ¿À¸®¾×ÅÍ Ç÷§Æû °£ÀÇ »óÈ£¿î¿ë¼ºÀ» º¸ÀåÇϱâ À§ÇÑ Ç¥ÁØÈ­ ³ë·ÂÀÌ ÇÊ¿äÇÕ´Ï´Ù.

¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡? ÁÖ¿ä È®´ë ¿äÀÎ ¹× »ê¾÷ µ¿Çâ ÆÄ¾Ç

¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍ ½ÃÀåÀÇ ¼ºÀåÀº »ý¹°ÇÐÀû Á¦Á¦ ¹× ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÚµ¿È­ ±â¼ú ¹ßÀü, ¹ÙÀÌ¿ÀÀǾàǰ ¿¬±¸ È®´ë µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. °íÈ¿À² ¾÷½ºÆ®¸² ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¦¾àȸ»çµéÀº È®Àå °¡´ÉÇÑ ¼Ò·® »ý»ê ¸ðµ¨¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó ¼Ò±Ô¸ð ¹ÙÀÌ¿À ¹ÝÀÀ±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¼Æ÷ ±â¹Ý Ä¡·á, À¯ÀüÀÚ Ä¡·á, ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ¿¬±¸ÀÇ ¿ªÇÒÀÌ È®´ëµÊ¿¡ µû¶ó ¿¬±¸ÀÚµéÀº Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ ÃÖÀûÈ­µÈ ¼¼Æ÷¹è¾ç ȯ°æÀ» ã°í ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó ½ÃÀåÀº ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ ±â¼úÀÇ Ã¤Åõµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, Ãʱ⠴ܰèÀÇ ¹ÙÀÌ¿À »ý»ê¿¡ ºñ¿ë È¿À²ÀûÀ̰í À¯¿¬ÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰ ¿¬±¸°³¹ßÀÌ Áö¼ÓÀûÀ¸·Î ¼ºÀåÇÔ¿¡ µû¶ó, ¼ÒÇü ¹ÙÀÌ¿À¸®¾×ÅÍ´Â ÀǾàǰ °³¹ß, °øÁ¤ ÃÖÀûÈ­, ¹ÙÀÌ¿À Á¦Á¶ Çõ½Å °¡¼ÓÈ­¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(Àç»ç¿ë °¡´É ¹ÙÀÌ¿À¸®¾×ÅÍ, ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ), ÃÖÁ¾»ç¿ëÀÚ(Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, CRO¡¤CMO, Çмú¡¤¿¬±¸±â°ü)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå°ú °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è µµ¸ÞÀÎ Àü¹®°¡°¡ ¼±º°ÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Small-Scale Bioreactors Market to Reach US$5.5 Billion by 2030

The global market for Small-Scale Bioreactors estimated at US$2.4 Billion in the year 2024, is expected to reach US$5.5 Billion by 2030, growing at a CAGR of 14.8% over the analysis period 2024-2030. Reusable Bioreactors, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Single-Use Bioreactors segment is estimated at 17.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$632.1 Million While China is Forecast to Grow at 14.0% CAGR

The Small-Scale Bioreactors market in the U.S. is estimated at US$632.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$854.4 Million by the year 2030 trailing a CAGR of 14.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.3% and 12.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.0% CAGR.

Global Small-Scale Bioreactors Market - Key Trends & Drivers Summarized

Why Are Small-Scale Bioreactors Gaining Importance? Examining Their Role in Biopharmaceutical and Biotech Research

The increasing demand for biopharmaceuticals, vaccines, and cell-based therapies has driven the adoption of small-scale bioreactors, which serve as critical tools for research, process optimization, and early-stage drug development. Unlike large industrial bioreactors, small-scale bioreactors provide a controlled environment for culturing microorganisms, mammalian cells, and other biological systems in volumes ranging from a few milliliters to several liters. These bioreactors are essential in the biotechnology and pharmaceutical industries for optimizing cell growth conditions before scaling up to commercial production. Academic institutions, contract research organizations (CROs), and startup biotech firms also rely on small-scale bioreactors to conduct experimental studies, reducing costs and risks associated with large-scale manufacturing. With increasing investment in precision medicine, regenerative therapies, and synthetic biology, the demand for small-scale bioreactors continues to rise as companies seek efficient and scalable bioprocessing solutions.

How Are Technological Advancements Enhancing Small-Scale Bioreactors? Exploring Innovations in Automation, Monitoring, and Process Control

Technological innovations in small-scale bioreactors have significantly improved their efficiency, reproducibility, and automation capabilities. The integration of real-time monitoring systems, such as optical sensors and spectroscopy-based analytics, allows researchers to track key parameters like pH, dissolved oxygen, and nutrient levels with high precision. Automated control systems with artificial intelligence (AI) and machine learning algorithms enable adaptive adjustments to bioprocess conditions, optimizing cell culture performance. Additionally, single-use bioreactors have gained popularity, eliminating the need for extensive cleaning and sterilization while reducing cross-contamination risks. The development of miniaturized, high-throughput bioreactors has further accelerated research, enabling parallel experimentation with multiple bioprocess parameters simultaneously. As the need for reproducible and scalable bioprocesses grows, these advancements are shaping the future of biopharmaceutical production, making small-scale bioreactors indispensable in modern biotech research.

What Challenges Are Impacting the Small-Scale Bioreactor Market? Addressing Cost, Scalability, and Standardization Issues

Despite their growing adoption, small-scale bioreactors face challenges related to cost, scalability, and standardization. The initial investment in advanced bioreactors equipped with automated control systems can be high, limiting accessibility for smaller research labs and emerging biotech firms. Additionally, scaling up from small-scale to commercial production remains a challenge, as bioprocess parameters often require re-optimization during scale-up. The lack of universal standards in bioreactor design, particularly for single-use systems, can also create compatibility issues between different suppliers and bioprocess workflows. Furthermore, while automation improves efficiency, it requires skilled personnel to interpret data and optimize protocols, increasing training requirements. Addressing these challenges involves continued innovation in cost-effective designs, improved bioprocess modeling for seamless scale-up, and standardization efforts to ensure interoperability across bioreactor platforms.

What’s Driving the Growth of the Small-Scale Bioreactors Market? Identifying Key Expansion Factors and Industry Trends

The growth in the small-scale bioreactors market is driven by several factors, including increasing demand for biologics and personalized medicine, advancements in automation technology, and the expansion of biopharmaceutical research. The rising need for high-efficiency upstream bioprocessing has led pharmaceutical companies to invest in scalable small-batch production models, increasing demand for small-scale bioreactors. The expanding role of cell-based therapies, gene therapies, and microbiome research has further strengthened the market as researchers seek optimized cell culture environments for therapeutic development. The adoption of single-use bioreactor technologies has also contributed to market expansion, offering cost-effective and flexible solutions for early-stage bioproduction. As biopharmaceutical R&D continues to grow, small-scale bioreactors are expected to play a crucial role in accelerating drug development, process optimization, and biomanufacturing innovation.

SCOPE OF STUDY:

The report analyzes the Small-Scale Bioreactors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Reusable Bioreactors, Single-Use Bioreactors); End-User (Pharma & Biotech Companies, CROs & CMOs, Academic & Research Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â